The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

Publisher： Bentham Science Publishers

E-ISSN： 1875-6557 |4|4|293-299

ISSN： 1573-403x

Source： Current Cardiology Reviews, Vol.4, Iss.4, 2008-11, pp. : 293-299

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?

By  

Current Cardiology Reviews, Vol. 4, Iss. 2, 2008-05 ,pp. : 84-91

Bentham Science Publishers

Access to resources Recommend Favorite

Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention

By  

Current Cardiology Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 323-333

Bentham Science Publishers

Access to resources Recommend Favorite

Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?

By  

Current Cardiology Reviews, Vol. 14, Iss. 1, 2018-03 ,pp. : 45-52

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention

By  

Current Cardiology Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 223-230

Bentham Science Publishers

Access to resources Recommend Favorite

Myocardial Perfusion SPECT Imaging in Patients after Percutaneous Coronary Intervention

By  

Current Cardiology Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 98-103

Bentham Science Publishers

Access to resources Recommend Favorite